Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
Public ClinicalTrials.gov record NCT06745882. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Prospective Trial to Assess Real-world Outcomes and Predictive Biomarkers of Response to Pembrolizumab With or Without Chemotherapy in Black Patients With NSCLC
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a non-registrational, cohort study enrolling eligible Black patients diagnosed with histologically or cytologically, advanced/metastatic NSCLC without known EGFR/ALK/ROS1 tumor mutations, and who are ≥ 18 years of age, ECOG performance status 0-2, and may have detectable ctDNA at baseline.
Study identification
- NCT ID
- NCT06745882
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 318 participants
Conditions and interventions
Conditions
Interventions
- Cisplatin Drug
- Carboplatin Drug
- Pemetrexed Drug
- Pembrolizumab Drug
- Abraxane Drug
- Paclitaxel Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 12, 2025
- Primary completion
- Dec 31, 2029
- Completion
- Dec 31, 2029
- Last update posted
- Sep 20, 2026
2025 – 2030
United States locations
- U.S. sites
- 11
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Moffitt Cancer Center | Tampa | Florida | 33612 | Recruiting |
| Our Lady of the Lake Physician's Group | Baton Rouge | Louisiana | 70805 | Recruiting |
| University of Maryland Greenebaum Cancer Center | Baltimore | Maryland | 21201 | Recruiting |
| Sinai Hospital of Baltimore | Baltimore | Maryland | 21215 | Recruiting |
| Medstar Franklin Square | Baltimore | Maryland | 21237 | Recruiting |
| Johns Hopkins Sidney Kimmel Comprehensive Cancer Center | Baltimore | Maryland | 21287 | Recruiting |
| TidalHealth Peninsula Regional | Salisbury | Maryland | 20801 | Recruiting |
| Montefiore Medical Cancer Center | The Bronx | New York | 10461 | Recruiting |
| FirstHealth of the Carolinas, Inc. | Pinehurst | North Carolina | 28374 | Recruiting |
| Baptist Clinical Research Institute | Memphis | Tennessee | 38120 | Recruiting |
| Nashville General Hospital | Nashville | Tennessee | 37208 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06745882, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 20, 2026 · Synced Sep 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06745882 live on ClinicalTrials.gov.